In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jiangsu Hengrui Medicine Co., Ltd.

https://www.hrs.com.cn/index.html

Latest From Jiangsu Hengrui Medicine Co., Ltd.

Chinese ADC Developers Catch Up with Global Players In Advancing Key Payloads

Chinese pharma firms led by Kelun are moving fast to develop the next-generation of cytotoxic "warheads," a key component of antibody-drug conjugates, disclosed company executives at conference in Suzhou.

China Research & Development

Chinese Biopharma Tycoons Down But Not Out In Latest Global Billionaire Ranking

China continues to dominate the latest list of global billionaires and top execs from domestic pharma firms Hengrui and Hansoh ranked among the wealthiest overall in the country, along with the founder of vaccine maker Zhifei Bio. A number of top Chinese biopharma business executives also featured in the global top 100 billionaires list.

China Leadership

Chinese Newcomers Look For Niche Immuno-Oncology Opportunities

Chinese pharma companies are continuing to pile into the already overcrowded domestic anti-PD-1/L1 sector in China, but despite the competition and regulatory tightening, the latecomers are looking for opportunities in areas such as cervical and small cell lung cancer with relatively fewer contenders.

China ImmunoOncology

Deal Watch: Moderna, ElevateBio Subsidiary To Combine mRNA With Gene Editing

Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes unveil plan to merge and extend runway into 2024.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Radiopharmaceuticals, Contrast Agents
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Atridia Pty Ltd
    • Fujian Shengdi Pharmaceutical Co., Ltd.
    • Hengrui Therapeutics, Inc., Hengrui Pharmaceuticals, Fujian Shengdi Pharmaceutical Co., Ltd.
    • Jiangsu Hengrui Pharmaceutical Co., Ltd.
UsernamePublicRestriction

Register